Podcasts about blood institute nhlbi

Sifting through the overwhelming amount of books, news articles, social media influencers, pop-up speaker events, and retreats for menopause is overwhelming, confusing, and expensive. How should midlife women navigate menopause feeling lost, alone, and confused by conflicting information that is supposed to make us healthier, stronger, and more resilient?There's a lot of trial and error and good money spent on products, providers, treatments, and at-home devices that don't live up to their promises. Today, you will walk away with golden nuggets of evidence-based and practical strategies to help you navigate midlife and beyond. This episode covers how to know if the information that you are hearing or reading is evidence-based, why research on women in menopause is complicated to decipher, the nuances of weight resistance training versus cardio exercise, what's most important for midlife women nutritionally, and how to properly eat around your workouts. We also cover how to read protein powder labels and what to look for in amino acids, why creatine is a game-changer for women beyond muscle health, and how to strategize getting restorative sleep. Dr. Rachele Pojednic is an international authority on nutrition, supplementation, and physical activity interventions for muscle physiology, performance, and recovery. She received her PhD from Tufts University Friedman School of Nutrition Science and Policy and completed her postdoctoral training at Harvard Medical School at the Joslin Diabetes Center and Spaulding Rehabilitation Hospital. She has a faculty appointment at Stanford University and holds research appointments at the Institute of Lifestyle Medicine at Harvard Medical School and Edith Cowan University's Nutrition and Health Innovation Research Institute. She has received NIH research funding from the National Heart Lung and Blood Institute (NHLBI) and the Vermont Biomedical Research Network (VBRN), an NIH IDeA Network of Biomedical Research Excellence (INBRE) program. She currently serves on the Board of Governors for the American College of Sports Medicine (ACSM) Exercise Is Medicine® initiative. Dr. Pojednic has been an active fitness professional for over 20 years as a nutrition educator and coach for Olympic, Division I sports, and tactical athletes. She has a passion for science communication and is regularly featured in outlets such as NPR, Sirius Doctor Radio, Time, the Wall Street Journal, STAT News, Popular Science, Self, Shape, Women's Health, Forbes, and Runners World.Medical Disclaimer:By listening to this podcast, you agree not to use this podcast as medical advice or to make any lifestyle changes to treat any medical condition in yourself or others. Consult your physician for any medical issues that you may be having. This entire disclaimer also applies to any of the guests on my podcast.Connect with Rachele:Website: https://www.rachelepojednic.com/IG: @rachelepojednic2004 YouTube: @RachelePojednic_PhDCourses: https://strongprocess.com/Stay connected with JFW:Watch on my YouTube channel: https://www.youtube.com/@jillfooswellness/videosFollow me on Instagram: https://www.instagram.com/jillfooswellness/Follow me on Facebook: https://www.facebook.com/jillfooswellnessGrab discounts on my favorite biohacking products: https://www.jillfooswellness.com/health-productsEnjoy 20% savings and free shipping at Fullscript for your favorite supplements by leading brands:https://us.fullscript.com/welcome/jillfooswellnessSubscribe to the JFW newsletter at www.jillfooswellness.com and receive your FREE Guide on How To Increase Your Protein in 5 Easy Steps and your free Protein Powder Recipe Ebook. Schedule your complimentary 30-minute Zoom consultation here:https://calendly.com/jillfooswellness/30-minute-zoom-consultations

On tonight's show, I have Sean Coady with National Heart, Lung, and Blood Institute (NHLBI) & Chef Jamie Gwen!

According to the National Heart, Lung, and Blood Institute (NHLBI), 50–70 million Americans have sleep disorders, and one in three adults don't get enough uninterrupted sleep to maintain their health. Listen in to this week's GC episode to learn the physiology of sleep, why we need sleep, and what our role is in educating patients on sleep hygiene sleep disorders, and OTC vs. Non-OTC options. HOSTJen Moulton, BSPharmPresidentCEimpactGUESTEzequiel Medina, PharmDSleep Coach and PharmacistLive Love SleepPharmacists, REDEEM YOUR CPE HERE!CPE is available to Health Mart franchise members onlyTo learn more about Health Mart, click here: https://join.healthmart.com/CPE INFORMATIONLearning ObjectivesUpon successful completion of this knowledge-based activity, participants should be able to:1. Identify common sleep disorders and their impact on patient health and outcomes.2. Explain strategies for managing sleep disorders through pharmacological and non-pharmacological interventions in pharmacy practice.0.05 CEU/0.5 HrUAN: 0107-0000-24-263-H01-PInitial release date: 9/16/2024Expiration date: 9/16/2025Additional CPE details can be found here.

According to the National Heart, Lung, and Blood Institute (NHLBI), 50–70 million Americans have sleep disorders, and one in three adults don't get enough uninterrupted sleep to maintain their health. Listen in to this week's GC episode to learn the physiology of sleep, why we need sleep, and what our role is in educating patients on sleep hygiene sleep disorders, and OTC vs. Non-OTC options. HOSTJen Moulton, BSPharmPresidentCEimpactGUESTEzequiel Medina, PharmDSleep Coach and PharmacistLive Love SleepPharmacist Members, REDEEM YOUR CPE HERE! Not a member? Get a Pharmacist Membership & earn CE for GameChangers Podcast episodes! (30 mins/episode)CPE INFORMATION Learning ObjectivesUpon successful completion of this knowledge-based activity, participants should be able to:1. Identify common sleep disorders and their impact on patient health and outcomes.2. Explain strategies for managing sleep disorders through pharmacological and non-pharmacological interventions in pharmacy practice.0.05 CEU/0.5 HrUAN: 0107-0000-24-263-H01-PInitial release date: 9/16/2024Expiration date: 9/16/2025Additional CPE details can be found here.Follow CEimpact on Social Media:LinkedInInstagram

On today's episode of Danforth Dialogues, Dr. Valerie Montgomery Rice sits down with Dr. Gary H. Gibbons, Director of the National Heart, Lung, and Blood Institute (NHLBI) at the National Institutes of Health (NIH). Dr. Gibbons joined the Morehouse School of Medicine in 1999 and founded the Morehouse Cardiovascular Institute. Prior to founding the Cardiovascular Institute, Dr. Gibbons served on the faculties of Stanford University and Harvard Medical School. In this episode, you'll hear about Dr. Gibbons' experience growing up in the Germantown neighborhood of Philadelphia and the confidence and self-belief he developed in his early years. He shares his passion for entering the field of cardiology, the story around his decision to leave Harvard to  join the Morehouse School of Medicine, and the lessons he learned about engaging communities in a way that meets people where they are. Tune in to this episode of Danforth Dialogues for an enriching exploration of Dr. Gibbons' journey from Germantown to the forefront of cardiology.   RESOURCES RELATED TO THIS EPISODE Visit https://www.nhlbi.nih.gov/ Visit https://msmcvri.org/    CREDITS Theme Music

In this podcast, Dr. Ally Larkin, Dr. Carol Mansfield, and Dr. Robyn Cohen discuss their experience implementing Single Maintenance and Reliever Therapy (known as "SMART" or "MART"). SMART is included in the 2020 updates to the National Asthma Education and Prevention Program Asthma Management Guidelines and the 2021 updates to the Global Initiative for Asthma Strategy. In this discussion, they cover how they implemented SMART into their clinical practice, challenges they've faced making the change, how SMART has improved asthma management and control for their patients, and advice for providers seeking to implement SMART into their own practices. References:New NAEPP/NHLBI Guidelines (2020): Expert Panel Working Group of the National Heart, Lung, and Blood Institute (NHLBI) administered and coordinated National Asthma Education and Prevention Program Coordinating Committee (NAEPPCC); Cloutier MM, Baptist AP, Blake KV, Brooks EG, Bryant-Stephens T, DiMango E, Dixon AE, Elward KS, Hartert T, Krishnan JA, Lemanske RF Jr, Ouellette DR, Pace WD, Schatz M, Skolnik NS, Stout JW, Teach SJ, Umscheid CA, Walsh CG. 2020 Focused Updates to the Asthma Management Guidelines: A Report from the National Asthma Education and Prevention Program Coordinating Committee Expert Panel Working Group. J Allergy Clin Immunol. 2020 Dec;146(6):1217-1270. doi: 10.1016/j.jaci.2020.10.003. Erratum in: J Allergy Clin Immunol. 2021 Apr;147(4):1528-1530. PMID: 33280709; PMCID: PMC7924476.  New GINA Guidelines (2021): Reddel HK, Bacharier LB, Bateman ED, Brightling CE, Brusselle GG, Buhl R, Cruz AA, Duijts L, Drazen JM, FitzGerald JM, Fleming LJ, Inoue H, Ko FW, Krishnan JA, Levy ML, Lin J, Mortimer K, Pitrez PM, Sheikh A, Yorgancioglu AA, Boulet LP. Global Initiative for Asthma Strategy 2021: Executive Summary and Rationale for Key Changes. Am J Respir Crit Care Med. 2022 Jan 1;205(1):17-35. doi: 10.1164/rccm.202109-2205PP. PMID: 34658302; PMCID: PMC8865583.  Articles on Implementation: Reddel HK, Bateman ED, Schatz M, Krishnan JA, Cloutier MM. A Practical Guide to Implementing SMART in Asthma Management. J Allergy Clin Immunol Pract. 2022 Jan;10(1S):S31-S38. doi: 10.1016/j.jaip.2021.10.011. Epub 2021 Oct 16. PMID: 34666208.  Cloutier MM, Teach SJ, Lemanske RF Jr, Blake KV. The 2020 Focused Updates to the NIH Asthma Management Guidelines: Key Points for Pediatricians. Pediatrics. 2021 Jun;147(6):e2021050286. doi: 10.1542/peds.2021-050286. Epub 2021 May 3. PMID: 33941586; PMCID: PMC8168603.  Article on the Implementation Gap: Krings JG, Sekhar TC, Chen V, Blake KV, Sumino K, James AS, Clover AK, Lenze EJ, Brownson RC, Castro M. Beginning to Address an Implementation Gap in Asthma: Clinicians' Views of Prescribing Reliever Budesonide-Formoterol Inhalers and SMART in the United States. J Allergy Clin Immunol Pract. 2023 Sep;11(9):2767-2777. doi: 10.1016/j.jaip.2023.05.023. Epub 2023 May 26. PMID: 37245736.  

NEJM 1991;324:781-788Background A hallmark of post-myocardial infarction (MI) care in the 1980's was the monitoring and suppression of premature ventricular contractions (PVCs) via use of antiarrhythmic drugs. The practice was based on pathophysiologic rationale that PVC burden is a strong risk factor for sudden and non-sudden cardiac death following MI and thus, suppression must reduce death. PVC reduction was a seductive surrogate endpoint that was easy to measure and declare victory on, but it had never been tested in a proper RCT. The Cardiac Arrhythmia Suppression Trial (CAST) was sponsored by the National Heart, Lung and Blood Institute (NHLBI) and sought to test the hypothesis that suppression of asymptomatic or mildly symptomatic PVCs with antiarrhythmic therapy with encainide, flecainide, or moricizine after MI would reduce death due to arrhythmia.Patients Patients were eligible for enrollment 6 days to 2 years post MI with an average of ≥6 PVCs per hour on ambulatory monitoring of at least 18 hours duration, and no runs of VT of ≥15 beats at a rate of ≥120 bpm. An ejection fraction (EF) of ≤55% was required within 90 days of MI or ≤40% if recruited after 90 days. There was a run-in phase. Patients were only enrolled in the main trial if they had at least 80% suppression of PVCs and at least 90% suppression of runs of VT during an initial, open-label titration period. Initial open-label drug assignment was based, in part, on the EF. Flecainide was not given to patients with an EF of ≤30%. Moricizine was only used as a second line drug in patients with an EF of ≥30%.Baseline characteristics Baseline characteristics of the patients enrolled in the trial are not provided in the main manuscript and cannot be inferred from the results, tables or figures presented.Procedures Patients in whom arrhythmias were suppressed were randomly assigned to receive either the effective drug or its matching placebo. A detailed description of study procedures is not presented in the main manuscript. Compliance with the study drug was assessed in follow-up visits and based on pill counts of tablets returned but the schedule of these visits is not provided. Concomitant drug therapy was assessed at the time of the last visit, according to a standardized checklist.During the trial, patients could be instructed to discontinue the study drug based on the occurrence of the following events: ventricular tachycardia, significant increase in arrhythmia burden, disqualifying ECG changes including significant QT prolongation or bradycardia, new or worsened congestive heart failure, the need for treatment with an antiarrhythmic agent outside the entry criteria for the study, or any number of other adverse medical events divided into cardiovascular or non-cardiovascular events.Endpoints The primary endpoint of the study was death or cardiac arrest with resuscitation due to arrhythmia. The site PI was responsible for classifying each death without knowledge of the patient's assigned treatment. Secondary endpoints included cardiovascular and non-cardiovascular causes of death, disqualifying ventricular tachycardia without arrest, syncope, pacemaker implantation, recurrent MI, congestive heart failure, angina pectoris or coronary artery revascularization.Results Observation began on the day of randomization to blinded therapy and was censored on April 18, 1989, the date when the use of encainide and flecainide was discontinued by the Data and Safety Monitoring Board because the data indicated it was unlikely that benefit could be demonstrated, and it was likely that the drugs were harmful. The original CAST trial manuscript reports data on patients assigned to the encainide and flecainide groups. Moricizine use was continued and would be reported separately in the revised CAST II trial.1498 participants were randomized to receive either encainide, flecainide or their matching placebo and followed for an average of 10 months. Compliance with the assigned treatments was estimated to be >90% in 70% of all patients and was similar in the active-drug and placebo groups. Antiarrhythmic therapy significantly increased the relative risk of the primary endpoint of death or cardiac arrest due to arrhythmia (RR 2.64; 5.7% vs 2.2%; p=0.0004) and was associated with a number needed to harm (NNH) of approximately 29. It also increased the risk of all deaths and cardiac arrests (RR 2.38; 8.3% vs 3.5%; p=0.0001; NNH = 20); even those not associated with arrhythmia (2.3% vs 0.7%; p=0.01).Conclusions The CAST trial unexpectedly demonstrated that treatment of asymptomatic or mildly symptomatic PVCs in post-MI patients, with encainide and flecainide, increased death and cardiac arrests. From a chronological standpoint, it is the first major trial in cardiovascular medicine (perhaps all of medicine) that “reversed” a standard medical practice. In this case, one that was instituted and broadly adopted on the basis of pathophysiologic reasoning and one that targeted a surrogate endpoint. Thus, more than anything it highlights the importance of testing interventions in properly conducted RCTs prior to adoption and basing the analysis on hard outcomes that are meaningful to patients and society. How many practices in modern medicine are supported by high quality RCTs? It may be as low as 30-40%. Get full access to Cardiology Trial's Substack at cardiologytrials.substack.com/subscribe

This week on the Here's What We Know Podcast, join us in this enlightening episode as we dive deep into the world of chronic pain with our guest, Dr. Afton Hassett, an experienced pain psychologist and the author of “Chronic Pain Reset”.  She offers informative content about how stress and mental health are intertwined with physical discomfort and delves into various aspects of chronic pain—its effects, causes, and potential treatments. Listen in and discover valuable insights about how your emotions can affect your perception of discomfort, and learn practical strategies for dealing with persistent affliction. And together, let's unlock the power of positivity in healing!In this Episode:The Intersection of Mental and Physical Health Resilience in Managing Chronic PainThe Power of Social InteractionCustomizing Treatment PlansThe Neuroscience Behind Pain The Invisible Nature Of Pain The Role Of Physical Activity And Sleep In Managing Chronic Pain Negative Impact Of Modern Devices On Sleep Quality  Understanding Chronic PainThe Biopsychosocial Aspects of PainRewiring the Brain The Limitations Of Pharmaceuticals The Power Of Holistic Methods  Pain Relief Through Enjoyable Activities This episode is sponsored by:Reed Animal HospitalSterling Oak CabinetryAbout Afton:Dr. Afton Hassett is a licensed clinical psychologist and an Associate Professor in the Department of Anesthesiology at the University of Michigan. She received her BFA from Colorado State University and her doctorate from Alliant International University in San Diego, CA. As a principal investigator at the Chronic Pain & Fatigue Research Center, she conducts interdisciplinary research related to exploring the role of cognitive, affective, and behavioral factors in chronic pain populations. She has published over 100 peer-reviewed articles and is a leader in the field of resilience and pain research. Her work has focused on exploring positive emotions and affective balance in people with pain; health-related quality of life in adult and pediatric rheumatology patients; and novel interventions to promote resilience and self-management for individuals with chronic pain. She is committed to education for individuals at many levels including patients, undergraduate and graduate students, medical residents, post-docs, physicians, and other healthcare providers. Dr. Hassett is the Director of Clinical Pain Research at the Back & Pain Center and the Past President of the Association of Rheumatology Health Professionals – a division of the American College of Rheumatology. Current funding sources include National Institute of Nursing Research (NINR), National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institute of Child Health and Human Development (NICHD), National Heart Lung and Blood Institute (NHLBI), Centers for Disease Control (CDC) and the University of Michigan. With over $14M of research funding from the National Institutes of Health (NIH), Afton's mission is to bring evidence-based strategies from research and academic settings to the people themselves. Her life's work is dedicated to helping people with chronic pain live lives with less pain, greater happiness, and renewed purpose in life.Website: https://aftonhassett.comInstagram: https://www.instagram.com/aftonhassettLinkedin: https://www.linkedin.com/in/afton-hassett-1982b323www.GaryScottThomas.com

Synopsis: Joel Schneider, Ph.D. and Robert Kotin, Ph.D. are the President & CEO and Founder & Chief Technology Advisor, respectively, of Carbon Biosciences, an emerging leader in the development of novel parvovirus-derived gene therapies. Joel and Robert sit down with host Rahul Chaturvedi to discuss the arc of their careers, how the AAV field has changed over the last decade, and how they approach building out their team at Carbon. They also talk about Carbon's focus on cystic fibrosis and the implications of The Cystic Fibrosis Foundation investing in their Series A. Finally, they both weigh in on what excites them when thinking about the future of gene therapy. Biographies: Dr. Joel Schneider joined Carbon as CEO in 2022, after serving as Chief Operating Officer at Solid Biosciences. As Solid's first employee, he played an instrumental role in building the company's unique disease-focused business model. Dr. Schneider is an accomplished biosciences executive with a track record of achievement in identifying, developing, and financing high potential therapeutic modalities and has diverse leadership experiences across R&D, technical and corporate operations, and corporate development organizations. Dr. Schneider holds a Ph.D. from Rutgers University and an undergraduate degree from Brandeis University and is the author of numerous peer-reviewed articles related to Duchenne and stem cell biology. He completed a postdoctoral fellowship at Harvard University in the Department of Stem Cell and Regenerative Biology, where he characterized and developed the small molecules that enhance skeletal muscle regeneration. Dr. Robert Kotin has been a leader in adeno-associated virus (AAV) research for 35 years, focusing on the molecular biology of the virus's non-structural proteins and then leveraging this understanding to develop novel AAV vectors for somatic cell gene therapy. Beginning as a postdoctoral fellow at Cornell University Medical Center, Dr. Kotin discovered a common integration site for AAV DNA in human chromosome 19, which he designated AAVS1 locus. He spent most of his career in the Intramural Research Program at the National Heart, Lung, and Blood Institute (NHLBI) of the National Institutes of Health (NIH), first as a tenure-track investigator and then as a tenured senior investigator and Head of the Laboratory of Molecular Biology and Gene Therapy. While at the NIH, Dr. Kotin's laboratory invented and developed a scalable recombinant adeno-associated virus (rAAV) production process in Sf9 cells which was licensed by UniQure, ThermoFisher, Voyager, Biomarin, and others and was used to produce Glybera™, the first rAAV product granted regulatory agency approval for sale. Additional research from the Kotin lab resulted in the discovery of an AAV replicative product that has been described as closed-ended linear duplex DNA (ceDNA) and became the basis of the non-viral gene therapy company Generation Bio (NASDAQ: GBIO). Dr. Kotin served as vice president of virology and gene therapy at Voyager Therapeutics from 2014 to 2016. Since 2016, he has served as an adjunct professor at UMass Medical School, where his research interests include vectorizing and characterizing ancestral parvoviruses based on inferred sequences from endogenous virus elements (EVEs) as novel gene therapy vectors. Dr. Kotin earned his B.A. in biology from the University of California, Santa Cruz, and his doctorate in microbiology from Rutgers University and the University of Medicine and Dentistry of New Jersey (now Robert Wood Johnson Medical School).

Hear from Victoria Pemberton, RNC, MS, CCRC, project officer for the National Heart, Lung and Blood Institute (NHLBI), as she discusses the importance of heart health literacy and highlights ways nurse practitioners can effectively engage with patients to reduce heart disease risk. February is American Heart Month — the ideal time to remind your patients about the importance of making heart-healthy lifestyle changes. New resources from the NHLBI's The Heart Truth® program can help you empower patients to achieve their cardiovascular health goals.   The American Association of Nurse Practitioners® (AANP) offers continuing education (CE), tools and resources to support nurse practitioners (NPs) working to reduce the risk of heart disease. Members may opt to join the AANP Cardiology Community, complete AANP CE Center activities, attend sessions at the 2023 AANP National Conference in New Orleans June 20-25, download clinical practice briefs or access a variety of cardiology-related resources.   Additional Resources American Heart Month Outreach Toolkit. High Blood Pressure and Women. Pregnancy and Your Heart Health. Heart Disease Prevention.  Heart Smart Basics: What to Know to Keep Yours Healthy. My Heart Health Tracker.

HRRP stands for Hospital Readmissions Reduction Program, by the way. I wanted to encore this episode with Dr. Rishi Wadhera because it's a great representation of a common root cause reason why quality metrics sometimes don't end well in real life. This root cause is otherwise known as Goodhart's Law, and we dig into Goodhart's law later on in this healthcare podcast. But the actual and ultimate impact of HRRP is also a pretty good representation of the consequences, what happens, when you create a blunt-force policy that assumes hospitals with very different circumstances are the same. Before we kick in to the episode, I asked Dr. Wadhera, my guest today as aforementioned, if there'd been any updates regarding HRRP since this show originally aired last year; and he told me that two key pieces have come out this past month in JAMA journals calling out CMS (Centers for Medicare & Medicaid Services) to move on from/retire this policy: A Decade of Observing the Hospital Readmission Reductions Program—Time to Retire an Ineffective Policy Readmission Reduction as a Hospital Quality Measure: Time to Move on to More Pressing Concerns? Thanks so much to Dr. Steve Schutzer and also BoneDoc66 for your really nice reviews this past month. So appreciated … thank you so much! And here is your encore. Today's guest is Rishi Wadhera, MD, MPP. Dr. Wadhera authored a retrospective analysis in the BMJ about the HRRP, which we will talk about in this healthcare podcast. Dr. Wadhera is a cardiologist at Beth Israel Deaconess Medical Center. He also has a master's in public policy at the Harvard Kennedy School of Government and also a master's in public health from the University of Cambridge. But here's the larger epiphany that pertains to all value-based care and all quality metrics which Dr. Wadhera brings up in this healthcare podcast and which my nerd heart could not love more: Goodhart's Law. This law is the root of so very many problems. Goodhart's Law is this (which I learned from Dr. Wadhera): “When a measure becomes a target, it ceases to be a good measure.” In other words, when we set a goal, people will try to take a shortcut to the goal, regardless of the consequences. And sometimes the consequences, paradoxically, are to do worse at the goal. Maybe because bean counters and admins and maybe even goal-oriented clinicians themselves will go right to the end goal, inadvertently skipping a whole bunch of (it turns out) rate-critical steps. For example, teaching to the test may not lead to students who deeply understand a subject. And anyone trying to achieve value-based care success, improve quality, form collaborations, or make sales might want to remember that old proverb, “Sometimes the shortest way home is the long way around.”   You can learn more at Dr. Wadhera's Harvard Catalyst profile and the Beth Israel Deaconess Medical Center Web site.   Rishi K. Wadhera, MD, MPP, MPhil, is an assistant professor of medicine at Harvard Medical School, a cardiologist at Beth Israel Deaconess Medical Center (BIDMC), and the associate program director of the cardiovascular medicine fellowship at BIDMC. He is also health policy and equity researcher at the Richard A. and Susan F. Smith Center for Outcomes Research in Cardiology. Dr. Wadhera received his MD from the Mayo Clinic School of Medicine as well as an MPhil in public health as a Gates Cambridge Scholar from the University of Cambridge. He completed his internal medicine residency and cardiovascular medicine fellowship at Brigham and Women's Hospital in Boston. During this time, he also received a master's in public policy (MPP) at the Harvard Kennedy School of Government, with a focus on health policy. Dr. Wadhera's research spans questions related to healthcare access, quality, and disparities, as well as understanding how local, state, and national policy initiatives impact care delivery, health equity, and outcomes. Dr. Wadhera has published more than 80 articles to date, and he receives research support from the National Heart, Lung, and Blood Institute (NHLBI) and the National Institutes of Health (NIH)   03:30 What was the Hospital Readmissions Reduction Program intended to do? 05:22 Why did the Centers for Medicare & Medicaid (CMS) think some readmissions were preventable? 06:02 “The spirit of the Hospital Readmissions Reduction Program was to incentivize hospitals to improve … discharge planning, transitions of care, and post-discharge follow-up and care.” 06:58 How has research in the last few years changed the thoughts on the effectiveness of the Hospital Readmissions Reduction Program? 08:16 “The 30-day readmission measure—it's an incomplete measure.” 11:48 “I think patients … are smart, and they know what's going on.” 13:34 “What's happening is, we're just increasing the number of times they need to come back to the ER within that 30-day period.” 13:55 “The weird thing about the HRRP is that when it evaluates hospitals' 30-day readmission rates, it's a yes-no phenomenon.” 15:03 “What CMS does is, it risk adjusts … and that is what we should be doing.” 18:30 “This program has been incredibly regressive.” 19:04 “Poverty, neighborhood disadvantage, housing instability—these factors are out of hospitals' control.” 21:50 “Blunt policies like this that are rolled out nationally probably elicit mixed behavioral responses.” 22:06 “It just makes no sense to take resources away from hospitals.” 22:32 EP295 with Rebecca Etz, PhD. 23:47 What's the way to improve quality of care globally? 25:37 “CMS's approach to improving quality of care has really anchored … [that] to payment.” 26:08 “It's time for us to rethink what our approach to quality improvement should be.” 29:22 “Policy makers have an obligation to rigorously test the impact of these types of policies before they roll them out nationally.” 31:41 Can you scale healthcare nationally?   You can learn more at Dr. Wadhera's Harvard Catalyst profile and the Beth Israel Deaconess Medical Center Web site.   @rkwadhera of @BIDMChealth discusses #HRRP on our #healthcarepodcast. #healthcare #podcast #digitalhealth #vbc #hospitalreadmission What was the Hospital Readmissions Reduction Program intended to do? @rkwadhera of @BIDMChealth discusses #HRRP on our #healthcarepodcast. #healthcare #podcast #digitalhealth #vbc #hospitalreadmission Why did CMS think some readmissions were preventable? @rkwadhera of @BIDMChealth discusses #HRRP on our #healthcarepodcast. #healthcare #podcast #digitalhealth #vbc #hospitalreadmission “The spirit of the Hospital Readmissions Reduction Program was to incentivize hospitals to improve … discharge planning, transitions of care, and post-discharge follow-up and care.” @rkwadhera of @BIDMChealth discusses #HRRP on our #healthcarepodcast. #healthcare #podcast #digitalhealth #vbc #hospitalreadmission How has research in the last few years changed the thoughts on the effectiveness of the Hospital Readmissions Reduction Program? @rkwadhera of @BIDMChealth discusses #HRRP on our #healthcarepodcast. #healthcare #podcast #digitalhealth #vbc #hospitalreadmission “The 30-day readmission measure—it's an incomplete measure.” @rkwadhera of @BIDMChealth discusses #HRRP on our #healthcarepodcast. #healthcare #podcast #digitalhealth #vbc #hospitalreadmission “What CMS does is, it risk adjusts … and that is what we should be doing.” @rkwadhera of @BIDMChealth discusses #HRRP on our #healthcarepodcast. #healthcare #podcast #digitalhealth #vbc #hospitalreadmission “Blunt policies like this that are rolled out nationally probably elicit mixed behavioral responses.” @rkwadhera of @BIDMChealth discusses #HRRP on our #healthcarepodcast. #healthcare #podcast #digitalhealth #vbc #hospitalreadmission “It just makes no sense to take resources away from hospitals.” @rkwadhera of @BIDMChealth discusses #HRRP on our #healthcarepodcast. #healthcare #podcast #digitalhealth #vbc #hospitalreadmission What's the way to improve quality of care globally? @rkwadhera of @BIDMChealth discusses #HRRP on our #healthcarepodcast. #healthcare #podcast #digitalhealth #vbc #hospitalreadmission “It's time for us to rethink what our approach to quality improvement should be.” @rkwadhera of @BIDMChealth discusses #HRRP on our #healthcarepodcast. #healthcare #podcast #digitalhealth #vbc #hospitalreadmission Can you scale healthcare nationally? @rkwadhera of @BIDMChealth discusses #HRRP on our #healthcarepodcast. #healthcare #podcast #digitalhealth #vbc #hospitalreadmission   Recent past interviews: Click a guest's name for their latest RHV episode! Ge Bai (Encore! EP356), Dave Dierk and Stacey Richter (INBW37), Merrill Goozner, Betsy Seals (EP387), Stacey Richter (INBW36), Dr Eric Bricker (Encore! EP351), Al Lewis, Dan Mendelson, Wendell Potter, Nick Stefanizzi, Brian Klepper (Encore! EP335), Dr Aaron Mitchell (EP382), Karen Root, Mark Miller, AJ Loiacono, Josh LaRosa, Stacey Richter (INBW35), Rebecca Etz (Encore! EP295), Olivia Webb (Encore! EP337), Mike Baldzicki, Lisa Bari, Betsy Seals (EP375), Dave Chase, Cora Opsahl (EP373), Cora Opsahl (EP372), Dr Mark Fendrick (Encore! EP308), Erik Davis and Autumn Yongchu (EP371), Erik Davis and Autumn Yongchu (EP370)

Atrial Fibrillation (AFib) and Venous Thromboembolism (VTE) have a risky bidirectional relationship. Hear from Carol Patrick, RNFA, ACNP-BC, FPCNA, as she explores this relationship and the different management and prevention techniques. Learn also about how cancer can increase a patient's risk for AFib and VTE. PCNA AFib Resources: https://pcna.net/clinical-resources/provider-tools/atrial-fibrillation-provider-tools/ PCNA VTE Resources: https://pcna.net/clinical-resources/patient-handouts/vte-and-blood-clot-tools-and-handouts/Atherosclerosis Risk in Community (ARIC) Study: https://onlinelibrary.wiley.com/doi/10.1111/jth.13974Pulmonary Embolism and Atrial Fibrillation: Two Sides of the Same Coin? A Systematic Review: https://www.thieme-connect.de/products/ejournals/abstract/10.1055/s-0036-1598005Differential Presentations of Arterial Thromboembolic Events Between Venous Thromboembolism and Atrial Fibrillation Patients: https://www.frontiersin.org/articles/10.3389/fcvm.2021.775564/fullAmerican College of Cardiology, Atrial Fibrillation: Guideline For the Management of Patients: https://www.acc.org/guidelines/hubs/atrial-fibrillationAmerican College of Chest Physicians (CHEST): https://www.chestnet.org/Anticoagulation FORUM, DOAC Playbook: https://acforum-excellence.org/Resource-Center/downloads/DOAC%20Playbook%20_07-2021.pdfNational Blood Clot Alliance: stoptheclot.orgNational Heart, Lung, and Blood Institute (NHLBI): https://www.nih.gov/about-nih/what-we-do/nih-almanac/national-heart-lung-blood-institute-nhlbiWorld Thrombosis Day (WTD): https://www.worldthrombosisday.org/about/wtd/Atrial fibrillation and cancer – An unexplored field in cardiovascular oncology: https://www.sciencedirect.com/science/article/abs/pii/S0268960X18301012?via%3DihubSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Lenora Johnson, DrPH, MPH directs the science policy, engagement, health education, and public-facing communication initiatives of the National Heart, Lung, and Blood Institute (NHLBI) at the National Institute of Health (NIH). This office supports and coordinates the public facing messaging and information delivery channels on behalf of NHLBI. One of the many projects Dr. Johnson works with […] The post Building Trust with Each Audience (HLOL #226) appeared first on Health Literacy Out Loud Podcast.

Continuing education episode! If a research project has been going on for over 30 years, you would think it's probably pretty good, right? Well, that's how long the REDS research project, sponsored by the US National Heart, Lung, and Blood Institute (NHLBI) has been breaking new ground in Transfusion Medicine. The two co-chairs of the fourth phase, REDS-IV-P, are here to explain why the best is yet to come!

In this episode, Ayesha shared insights she obtained from experts at NIH's National Heart, Lung and Blood Institute (NHLBI) about clinical trial diversity. The panel of experts outlined some of the challenges in recruiting participants from minority and disadvantaged socioeconomic backgrounds, and talked about an NHLBI initiative based on community outreach that helped recruit more participants from traditionally underrepresented groups for COVID-19 vaccine trials. The editorial team also talked about the theme of this year's World Health Day 2022, which is “our planet, our health.” The theme relates to new WHO data that shows most of the world is breathing polluted air. This is of great significance and concern as environmental causes are a leading cause of death worldwide. Learn about the initiatives and updated guidelines that the WHO has issued to help address the worsening quality of air globally, and hear our team's thoughts on how environmental responsibilities should be shared.Read the full articles here: Xtalks Voices: NIH Experts Share Insights on Increasing Clinical Trial DiversityWorld Health Day 2022: WHO Data Shows 99 Percent of People Breathe Poor Quality AirFor more life science and medical device content, visit the Xtalks Vitals homepage.Follow Us on Social MediaTwitter: @Xtalks Instagram: @Xtalks Facebook: https://www.facebook.com/Xtalks.Webinars/ LinkedIn: https://www.linkedin.com/company/xtalks-webconferences YouTube: https://www.youtube.com/c/XtalksWebinars/featured

In this episode, we will be interviewing Dr. Jennifer Shieh, Chief Scientist and Program Manager Office of Innovation and Technology Office of Investment and Innovation U.S. Small Business Administration. She advances technology commercialization through the Small Business Innovation Research/Small Business Technology Transfer (SBIR/STTR) programs, building partnerships and coordinating policy across the 11 participating Federal agencies. She served as the Assistant Director for Entrepreneurship at the White House Office of Science and Technology Policy (OSTP), where she led national efforts to improve the transfer of federally-funded technologies from lab-to-market, advance Federal agency coordination on R&D infrastructure, and champion open innovation through prizes and citizen science. Previously, she managed the Small Business Program for the National Heart, Lung, and Blood Institute (NHLBI) and served as a Program Director at the National Cancer Institute (NCI) SBIR Development Center, having joined NCI as an AAAS Science and Technology Policy Fellow. She was involved in product and customer development at Syapse, a precision medicine-focused startup, and mobile games startup Subversus Interactive. Dr. Shieh studied the brain and cognitive sciences at MIT then earned her Ph.D. in neurosciences at Stanford University. She is co-author of the textbook Guide to Research Techniques in Neuroscience. Visit the page: https://www.sbir.gov/about/leadership --- Send in a voice message: https://anchor.fm/governmentcoins/message Support this podcast: https://anchor.fm/governmentcoins/support

In this episode, we will be interviewing Dr. Jennifer Shieh, Chief Scientist and Program Manager Office of Innovation and Technology Office of Investment and Innovation U.S. Small Business Administration. She advances technology commercialization through the Small Business Innovation Research/Small Business Technology Transfer (SBIR/STTR) programs, building partnerships and coordinating policy across the 11 participating Federal agencies. She served as the Assistant Director for Entrepreneurship at the White House Office of Science and Technology Policy (OSTP), where she led national efforts to improve the transfer of federally-funded technologies from lab-to-market, advance Federal agency coordination on R&D infrastructure, and champion open innovation through prizes and citizen science. Previously, she managed the Small Business Program for the National Heart, Lung, and Blood Institute (NHLBI) and served as a Program Director at the National Cancer Institute (NCI) SBIR Development Center, having joined NCI as an AAAS Science and Technology Policy Fellow. She was involved in product and customer development at Syapse, a precision medicine-focused startup, and mobile games startup Subversus Interactive. Dr. Shieh studied the brain and cognitive sciences at MIT then earned her Ph.D. in neurosciences at Stanford University. She is co-author of the textbook Guide to Research Techniques in Neuroscience. Visit the page: https://www.sbir.gov/about/leadership --- Send in a voice message: https://anchor.fm/governmentcoins/message Support this podcast: https://anchor.fm/governmentcoins/support

Dr. Erik Jensen is an attending neonatologist in the division of neonatology at the Children's hospital of Philadelphia. He is an assistant professor of pediatrics at the Perelman School of Medicine at the University of Pennsylvania.Dr. Jensen's research seeks to improve the long-term respiratory health of premature infants through: (1) clinical and translational studies that aim to develop evidence-based strategies to prevent and treat BPD; (2) novel characterization of disease severity and phenotypes in BPD; and (3) application of health services research techniques to investigate the association between hospital-level factors and neonatal morbidity and mortality.Dr. Jensen's research is supported by grant funding from the National Heart Lung and Blood Institute (NHLBI), the National Institute of Child Health and Human Development (NICHD), and the American Lung Association (ALA). He is a member of the International BPD Collaborative pharmacology working group and the International Neonatal Consortium (INC) BPD working group. He has received multiple clinical and research awards. _____________________________________________________________________________________________________As always, feel free to send us questions, comments or suggestions to our email: nicupodcast@gmail.com. You can also contact the show through instagram or twitter, @nicupodcast. Or contact Ben and Daphna directly via their twitter profiles: @drnicu and @doctordaphnamd. enjoy!

Dr. Grandner is the Director of the Sleep and Health Research Program at the University of Arizona, Director of the Behavioral Sleep Medicine Clinic at the Banner-University Medical Center, and an Associate Professor in the Department of Psychiatry at the UA College of Medicine, with joint appointments in the Departments of Medicine, Psychology (UA College of Science), Nutritional Sciences (College of Agriculture and Life Sciences), and Clinical Translational Science. In addition, he is a faculty member of the Neuroscience and Physiological Sciences Graduate Interdisciplinary Programs. He is certified in Behavioral Sleep Medicine by the American Board of Sleep Medicine and is a Diplomate in Behavioral Sleep Medicine by the Board of Behavioral Sleep Medicine. His research focuses on how sleep and sleep-related behaviors are related to cardiovascular disease, diabetes, obesity, neurocognitive functioning, mental health, and longevity. Current and recently-completed research projects were funded by the National Institute on Minority Health and Health Disparities (NIMHD), the National Institute on Drug Abuse (NIDA), the National Heart, Lung, and Blood Institute (NHLBI), the National Institute for Environmental Health Sciences (NIEHS), the American Heart Association (AHA), the National Collegiate Athletic Association (NCAA), and other organizations. Read more about his research or see his publications. Find out more about Michael here https://www.michaelgrandner.com/about.html  Follow us for more information at www.sleep4performance.com.au     

Here's the context, friends: As you may have noticed over the past few episodes, we have been digging into value-based care here at Relentless Health Value corporate work-from-home headquarters. Many lessons have been learned, and it's important that we sit back and think hard every now and then about how we are going to use these learnings to improve. While this show tackles the Hospital Readmissions Reduction Program (HRRP)—and wow, I was glued to my seat during this interview—the show is really about more than that, which I'll get into in 30 seconds. But let's start here: HRRP was originally part of the Affordable Care Act in 2010. In 2012, HRRP began imposing penalties on hospitals with higher-than-expected 30-day readmission rates for three conditions: heart failure, myocardial infarction, and pneumonia. Spoiler alert: More recently, CABG, THA/TKA, and COPD were added to the list. So basically, if a patient is in the hospital for any of these six things and then is readmitted to the hospital for any reason within 30 days, penalties can happen. Today's guest is Rishi Wadhera, MD, MPP. Dr. Wadhera authored a retrospective analysis in the BMJ about the HRRP, which we will talk about in this health care podcast. His findings are fascinating and relevant on a number of levels.  Dr. Wadhera is a cardiologist at Beth Israel Deaconess Medical Center. He also has a master's in public policy at the Harvard Kennedy School of Government and also a master's in public health from the University of Cambridge. Dr. Wadhera works on policy at the Richard A. and Susan F. Smith Center for Outcomes Research in Cardiology.  But here's the larger epiphany that pertains to all value-based care and all quality metrics which Dr. Wadhera brings up in this health care podcast and which my nerd heart could not love more: Goodhart's Law. This law is the root of so very many problems. Goodhart's Law is this (which I learned from Dr. Wadhera): “When a measure becomes a target, it ceases to be a good measure.” In other words, when we set a goal, people will try to take a shortcut to the goal, regardless of the consequences. And sometimes the consequences, paradoxically, are to do worse at the goal. For example, teaching to the test may not actually lead to students who deeply understand a subject. Here's another example, and Rebecca Etz, PhD, talks about this in EP295: If you want PCPs to do an amazing job managing diabetes, for example, the best measures are ones that quantify the doctor's relationship with the patient and the amount of trust between them. The second you start using their panel's average A1C as the performance metric, A1Cs at best don't improve. Why? Bean counters and admins and maybe even goal-oriented clinicians themselves will go right to the end goal, inadvertently skipping a whole bunch of (it turns out) rate-critical steps. It doesn't go well. It's like salespeople who try to close before they build a relationship. Time to goal counterintuitively is slower, and performance is poorer. Anyone building value-based care or quality programs might really want to include Goodhart's Law in their thinking. And anyone trying to achieve value-based care success, improve quality, form collaborations, or make sales might want to remember that old proverb, “Sometimes the shortest way home is the long way around.” You can learn more at Dr. Rishi's Harvard Catalyst profile and the Beth Israel Deaconess Medical Center Web site. Rishi K. Wadhera, MD, MPP, MPhil, is an assistant professor of medicine at Harvard Medical School, a cardiologist at Beth Israel Deaconess Medical Center (BIDMC), and the associate program director of the cardiovascular medicine fellowship at BIDMC. He is also health policy and equity researcher at the Richard A. and Susan F. Smith Center for Outcomes Research in Cardiology. Dr. Wadhera received his MD from the Mayo Clinic School of Medicine as well as an MPhil in public health as a Gates Cambridge Scholar from the University of Cambridge. He completed his internal medicine residency and cardiovascular medicine fellowship at Brigham and Women's Hospital in Boston. During this time, he also received a master's in public policy (MPP) at the Harvard Kennedy School of Government, with a focus on health policy. Dr. Wadhera's research spans questions related to health care access, quality, and disparities, as well as understanding how local, state, and national policy initiatives impact care delivery, health equity, and outcomes. Dr. Wadhera has published more than 80 articles to date, and he receives research support from the National Heart, Lung, and Blood Institute (NHLBI) and the National Institutes of Health (NIH). 03:10 What was the Hospital Readmissions Reduction Program intended to do? 05:05 Why did the Centers for Medicare & Medicaid (CMS) think some readmissions were preventable? 05:46 “The spirit of the Hospital Readmissions Reduction Program was to incentivize hospitals to improve … discharge planning, transitions of care, and post-discharge follow-up and care.” 06:54 How has research in the last few years changed the thoughts on the effectiveness of the Hospital Readmissions Reduction Program? 08:14 “The 30-day readmission measure—it's an incomplete measure.” 12:12 “I think patients … are smart, and they know what's going on.” 14:01 “What's happening is, we're just increasing the number of times they need to come back to the ER within that 30-day period.” 14:22 “The weird thing about the HRRP is that when it evaluates hospitals' 30-day readmission rates, it's a yes-no phenomenon.” 15:30 “What CMS does is, it risk adjusts … and that is what we should be doing.” 19:16 “This program has been incredibly regressive.” 19:51 “Poverty, neighborhood disadvantage, housing instability—these factors are out of hospitals' control.” 22:56 “Blunt policies like this that are rolled out nationally probably elicit mixed behavioral responses.” 23:12 “It just makes no sense to take resources away from hospitals.” 25:22 What's the way to improve quality of care globally? 27:19 “CMS's approach to improving quality of care has really anchored … [that] to payment.” 27:49 “It's time for us to rethink what our approach to quality improvement should be.” 31:28 “Policy makers have an obligation to rigorously test the impact of these types of policies before they roll them out nationally.” 34:05 Can you scale health care nationally? You can learn more at Dr. Rishi's Harvard Catalyst profile and the Beth Israel Deaconess Medical Center Web site. @rkwadhera of @BIDMChealth discusses #HRRP on our #healthcarepodcast. #healthcare #podcast #digitalhealth #vbc #hospitalreadmission What was the Hospital Readmissions Reduction Program intended to do? @rkwadhera of @BIDMChealth discusses #HRRP on our #healthcarepodcast. #healthcare #podcast #digitalhealth #vbc #hospitalreadmission Why did CMS think some readmissions were preventable? @rkwadhera of @BIDMChealth discusses #HRRP on our #healthcarepodcast. #healthcare #podcast #digitalhealth #vbc #hospitalreadmission “The spirit of the Hospital Readmissions Reduction Program was to incentivize hospitals to improve … discharge planning, transitions of care, and post-discharge follow-up and care.” @rkwadhera of @BIDMChealth discusses #HRRP on our #healthcarepodcast. #healthcare #podcast #digitalhealth #vbc #hospitalreadmission How has research in the last few years changed the thoughts on the effectiveness of the Hospital Readmissions Reduction Program? @rkwadhera of @BIDMChealth discusses #HRRP on our #healthcarepodcast. #healthcare #podcast #digitalhealth #vbc #hospitalreadmission “The 30-day readmission measure—it's an incomplete measure.” @rkwadhera of @BIDMChealth discusses #HRRP on our #healthcarepodcast. #healthcare #podcast #digitalhealth #vbc #hospitalreadmission “What CMS does is, it risk adjusts … and that is what we should be doing.” @rkwadhera of @BIDMChealth discusses #HRRP on our #healthcarepodcast. #healthcare #podcast #digitalhealth #vbc #hospitalreadmission “Blunt policies like this that are rolled out nationally probably elicit mixed behavioral responses.” @rkwadhera of @BIDMChealth discusses #HRRP on our #healthcarepodcast. #healthcare #podcast #digitalhealth #vbc #hospitalreadmission “It just makes no sense to take resources away from hospitals.” @rkwadhera of @BIDMChealth discusses #HRRP on our #healthcarepodcast. #healthcare #podcast #digitalhealth #vbc #hospitalreadmission What's the way to improve quality of care globally? @rkwadhera of @BIDMChealth discusses #HRRP on our #healthcarepodcast. #healthcare #podcast #digitalhealth #vbc #hospitalreadmission “It's time for us to rethink what our approach to quality improvement should be.” @rkwadhera of @BIDMChealth discusses #HRRP on our #healthcarepodcast. #healthcare #podcast #digitalhealth #vbc #hospitalreadmission Can you scale health care nationally? @rkwadhera of @BIDMChealth discusses #HRRP on our #healthcarepodcast. #healthcare #podcast #digitalhealth #vbc #hospitalreadmission

In this CME episode intended for allergists and other healthcare professionals, Michelle M. Cloutier, MD, Chair of the Expert Panel Working Group of the National Asthma Education and Prevention Program Coordinating Committee that is coordinated by the National Heart, Lung, and Blood Institute (NHLBI), discusses important aspects of the NHLBI’s newly released 2020 asthma guidelines during this in-depth and comprehensive interview. Listen now to learn more about what the guidelines do and do not address, as well as important perspective about how to put these recommendations into practice.

Have you ever wondered about the interaction of dieting in relation to circus or aerial training? In this episode of CircSci, we look at intermittent fasting and keto diets and whether they make sense for circus athletes with Dr. Ethan Weiss. Dr. Weiss is an Associate Professor of Medicine at the University of California, San Francisco, and a Principle Investigator in the Cardiovascular Research Institute (CVRI). He received his M.D. from Johns Hopkins University School of Medicine, where he also completed his internship and residency. He completed his cardiology training at UCSF. Dr. Weiss' clinical interests include prevention, lipids, thrombosis and the emerging intersection of endocrinology and cardiology with a specific focus on pre-diabetes and Type 2 diabetes as risk factors for coronary disease. His research is focused on the mechanisms of obesity, fatty liver disease, and diabetes. He has an active program in clinical nutrition exploring time-restricted eating. He has served as Principle Investigator on grants funded by the National Heart, Lung, and Blood Institute (NHLBI) and National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). His laboratory previously focused on novel regulators of thrombosis and hemostasis. He serves on multiple scientific advisory boards and is a co-founder of Keyto Inc., a San Francisco-based company aiming to enable the use of a heart healthy ketogenic diet to treat metabolic diseases.

In this episode, Dr. Richard Childs, a senior investigator and Clinical Director of the National Heart, Lung, and Blood Institute (NHLBI), recounts his experience using the antiviral remdesivir to treat patients with COVID-19 in one of the early hot zones of the pandemic. He led a team sent to care for passengers on the Diamond Princess cruise ship that was held in quarantine in Yokohama, Japan at the start of the outbreak. Since then, remdesivir has continued to gain traction as a possible standard of care. Dr. Matthew Hall, biology group leader at the National Center for Advancing Translational Sciences (NCATS), explains the development of the drug and its newfound purpose in the battle against the novel coronavirus.  

Hosted by: Dr. Danielle Belardo Instagram: @theveggiemd Twitter: @theveggiemd Facebook: The Veggie MD Produced by: Dr. Kasey Johnson Instagram: @drkaseyjohnson This is the episode everyone has been waiting for... it’s all about plant based keto! Featuring cardiologist Dr. Ethan Weiss and orthopedic surgeon/thriving Type 1 Diabetic Dr. Carrie Diulus. Did you know you can follow a keto diet that’s actually heart healthy? Low in saturated fat, and high in fiber and polyunsaturated and monounsaturated fat, a plant based keto diet is a promising tool for individuals struggling with appetite and obesity. In this episode we discuss: What is a plant based keto diet? How can it be beneficial for obesity, appetite suppression and weight loss ? How can a plant based keto diet potentially help individuals with diabetes and high cholesterol? What’s the difference between plant based keto and animal based keto (hint—- there ARE MANY!) And many more... Interested in trying it? Check out this plant based keto meal plan from Keyto: (FYI this is NOT a paid partnership, I have ZERO financial affiliation with this company, I just believe in their program!) http://shop.getkeyto.com/pages/key-eats-plant-based As with ANY dietary change***please consult with your physician/healthcare provider before making any changes.   About Dr. Ethan Weiss: Instagram @ethanjweiss Twitter @ethanjweiss Dr. Weiss is an Associate Professor of Medicine at the University of California, San Francisco, and a Principle Investigator in the Cardiovascular Research Institute (CVRI). He received his M.D. from Johns Hopkins University School of Medicine, where he also completed his internship and residency. He came to UCSF in 1998 to complete his cardiology fellowship and research training.  Dr. Weiss’ clinical interests include prevention, lipids, and the emerging intersection of endocrinology and cardiology with a specific focus on pre-diabetes and Type 2 diabetes as risk factors for coronary disease. His research interests are focused on understanding the mechanisms of metabolic disorders such as obesity, fatty liver disease, and diabetes including the role of growth hormone signaling and lipid metabolism. He also has an active program in clinical nutrition. He has served as Principle Investigator on grants funded by the National Heart, Lung, and Blood Institute (NHLBI) and National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). He serves on the scientific advisory boards of multiple companies focused on using technology to favorably impact human health. Lastly, he is a recent co-founder of Keyto Inc., a San Francisco-based company aiming to enable the use of a heart healthy ketogenic diet for weight loss.   About Dr. Carrie Diulus Instagram @carriediulusmd Twitter: @cadiulus Dr. Carrie Diulus is a board certified orthopedic spine surgeon, previously trained as a pathologist. She is also a thriving Type 1 diabetic and distance runner. She was morbidly obese when she started medical school and has done extensive personal dietary experimentation, most of her life being plant based, to lose and maintain that weight loss. She previously worked at the Cleveland Clinic but now is in private practice at the Crystal Clinic in Akron Ohio. She is leading the charge to bring dietary strategies to the forefront in prevention and treatment of musculoskeletal and spinal conditions related to metabolic syndrome. 

Our blood is made up of a diverse array of different cells, all of which originate from the same source: the ‘hematopoietic’ stem cells in our bone marrow. Dr. Cynthia Dunbar is a clinician working to understand how these stem cells grow, divide, and ultimately produce the cells that carry oxygen around the body and fight disease. Learning to safely transplant and manipulate hematopoietic stem cells could lead to treatments for a wide variety of diseases caused by a lack of properly functioning blood cells, including leukemia and aplastic anemia.  Cynthia Dunbar, M.D., is a Principal Investigator in the Molecular Hematopoiesis Section at the NIH's National Heart, Lung, and Blood Institute (NHLBI). Learn more about Dr. Dunbar and her research at https://irp.nih.gov/pi/cynthia-dunbar

In this rapid-fire and powerful podcast, we talk about what constitutes as heart disease and the discussion around the risk factors that contribute towards heart disease. We touch basis on concerns with fats and even delve into processed foods, pharmaceutical industry and the challenges of our modern health care system. This one is LOADED! BIO: Dr. Ethan Weiss is a Principle Investigator in the Cardiovascular Research Institute (CVRI). Dr. Weiss received his M.D. from Johns Hopkins University School of Medicine where he also completed his internship and residency. He came to UCSF in 1998 to complete his cardiology fellowship and research training. Dr. Weiss' clinical interests include prevention, lipids, and the emerging intersection of endocrinology and cardiology with a specific focus on pre-diabetes and type 2 diabetes as risk factors for coronary disease. In addition, he has interests in the genetics of coronary disease, cardiovascular risk assessment, nutrition and lifestyle, and heart disease in the young. He works with his patients to use rational and evidence-based approaches - including lifestyle modifications and where necessary, drug therapy - to improve cardiovascular risk. His research interests are focused on understanding the mechanisms of metabolic disorders such as obesity, fatty liver disease, and diabetes including the role of growth hormone signaling and lipid metabolism. He also has an active program in clinical nutrition. He has severed as Principle Investigator on grants funded by the National Heart Lung and Blood Institute (NHLBI) and National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). He serves on the scientific advisory boards of multiple companies focused on using technology to favorably impact human health. Lastly, he is a recent co-founder of, Keyto Inc. (www.getkeyto.com), a new San Francisco based company aiming to facilitate the use of the ketogenic diet for weight loss. TIME STAMPS: 0:15 – Ketogeek Energy Pods, Affiliate Program Update & Miscellaneous 12:55 – Dr. Weiss’s journey into Cardiology and being a jack of all trades 17:59 – What exactly is “heart disease”? 21:10 – Risk factors and modeling of heart disease 23:12 – How can you map out heart disease from observational and controlled trials? 25:25 – A discussion about LDL cholesterol 31:35 – The role of triglycerides in the risk of heart disease 34:46 -  If you could take one diet with you, what would it be? 38:28 – What about concerns with seed oils? 40:50 – What about concerns with saturated fats? 43:57 – How to deal with sensationalist media scares about food? 49:03 – How would we deal with modern foods consumer demands such as vegan meats? 51:30 – Are we getting healthier? 54:03 – What about statins and the allegations against the drug industry? 59:33 – How do you find a health specialist nowadays? 1:02:17 – What does “Keyto” do? 1:0 3:55 – New studies you’re doing right now? 1:06:55 – Final Plugs GUEST LINKS: Twitter: https://twitter.com/ethanjweiss UCSF Link: https://profiles.ucsf.edu/ethan.weiss Get Keyto Website: https://shop.getkeyto.com/ Get Keyto Twitter: https://twitter.com/GetKeyto Keyto Instagram: https://www.instagram.com/keyto.health/ KETOGEEK LINKS: Shop Energy Pods Amazon: https://www.amazon.com/Ketogeek-Chocolate-Energy-Organic-Vanilla/dp/B07B88S36J Ketogeek Ghee on Amazon: https://www.amazon.com/dp/B07B29HM3D Ketogeek Merchandise, Ghee & Energy Pods: https://ketogeek.com/collections Ketogeek Newsletter: https://ketogeek.com/pages/sign-up Shop Energy Pods: https://ketogeek.com/collections/energy-pods Wholesale: https://ketogeek.com/pages/wholesale  

Psoriasis is an inflammatory skin disease associated with increased cardiovascular risk. Dr. Nehal Mehta currently directs the largest ongoing cohort study to date in psoriasis, and his research is showing that local inflammation in different areas of the body such as the teeth, scalp, knees, skin, or gut has systemic consequences, and treating that local inflammation can help heal heart disease. Nehal Mehta, M.D., M.S.C.E., F.A.H.A., is the inaugural NIH Lasker Clinical Research Scholar and a Principal Investigator in the Section of Inflammation and Cardiometabolic Diseases at the NIH's National Heart, Lung, and Blood Institute (NHLBI). Learn more about Dr. Mehta and his research at https://irp.nih.gov/pi/nehal-mehta

Azizi A. Seixas, Ph.D., assistant professor at NYU School of Medicine, in the Department of Population Health and the Center for Healthful Behavior Change, provides an interesting overview of the power of sleep, and the problems we could face when sleep is low quality or we simply don't get enough. Dr. Seixas has devoted his career to understanding and addressing the sociocultural and environmental determinants of chronic diseases. Dr. Seixas received an MA from Fordham University and was an advanced doctoral candidate in clinical psychology there. Additionally he received an MS in clinical psychology from The University of Dallas, and a BA​ ​in philosophy and premed studies from College of the Holy Cross. Dr. Seixas discusses the four behaviors that he considers the pillars of health: physical activity, diet, stress management, and sleep. He states that of the four, sleep has been shown to be implicated in cardiovascular disease, metabolic health conditions, brain health, daily function, and overall quality of life.  Dr. Seixas' research focuses on three areas: multilevel determinants of sleep and cardiovascular disease disparities; the long-term health results of cardiovascular disease (CVD) disparities; and developing adaptive, group-tailored, specific and personalized behavior modification interventions, incorporating machine learning analytical tools, to improve overall health and general well being. Dr. Seixas addresses the important sociocultural and environmental determinants of various chronic diseases and behaviors, that often prevent access to basic care in certain disadvantaged communities that are burdened by adverse cardiovascular outcomes in a disproportionate manner. Dr. Seixas‘ work looks at the barriers that hinder diagnosis and treatment of sleep disorders within racial/ethnic minorities and seeks to evaluate the efficacy of behavioral models targeted at improving a commitment to sleep and CVD recommended types of therapies. Dr. Seixas talks about the ways they reach out to the community, by literally going to retail community shops, such as barbershops and hair salons, to talk to people and work with them. He discusses the sleep education and social support that they offer to at-risk individuals. By introducing a home-based sleep study, and allowing people to avoid going to a clinic for the study they have found a way to offer more significant help to communities, targeting at-risk individuals, testing them, and helping put them on a path toward better health.  Dr. Seixas was awarded a National Heart, Lung, and Blood Institute (NHLBI) career award to research as to whether inadequate sleep and/or obesity could possibly explain a notable proportion of CVD risk disparity between blacks and whites, through secondary data analysis of the Sleep Heart Health Study. Dr. Seixas details how simply getting more quality sleep can affect so many areas in our lives, from sex drive to mood, functioning to mental clarity, and so many other serious health issues. In addition to his work that focuses on population health insights, he is also working on developing precise and personalized behavioral medicine solutions that use artificial intelligence to optimize behavior change and adherence to pro-health behaviors.

Michael A. Grandner, PhD, Arizona College of Medicine, provides an overview of the many aspects of sleep, how it impacts functioning, and the ways we can improve the quality of our sleep. Dr. Grandner is an experienced researcher, noted speaker, and respected colleague at many prestigious institutions. He serves as the director of the Sleep and Health Research Program at the University of Arizona, and as director of the Behavioral Sleep Medicine Clinic at the Banner-University Medical Center. Additionally, Dr. Grandner is an assistant professor in the departments of psychiatry and medicine in the UA College of Medicine, assistant professor of psychology in the UA College of Science, as well as an assistant professor of nutritional sciences in the College of Agriculture and Life Sciences. He is certified in behavioral sleep medicine by the American Board of Sleep Medicine. Dr. Grandner discusses the connections between sleep and health and how it plays an important role in many and various areas of functioning. He states that a lot of their research focuses on finding ways to help with sleep improvement. He looks at quality and quantity of sleep, timing, when people are sleeping, and why. He gives details on the range of ways they study sleep in their laboratory. He talks about the various types of emerging technologies that can assist them with measuring the aspects of sleep. As sleep exists deep in the brain, it is impossible to perfectly measure sleep, thus Dr. Grandner states that they must measure around it, guessing at other measures such as movement and brain wave activity, etc. Achieving healthy sleep is crucial for great overall health, cardiovascular health, and is also an important factor in obesity, diabetes, and psychological well being. And as such, when we don't get enough of it, or the quality level is low, functioning can be impacted in many ways. Interestingly, Dr. Grandner points out that many people actually degrade their own opportunity to achieve quality sleep by reinforcing periods of insomnia. As he states, the best thing to do when you're in bed and can't sleep is to get up. Lying in bed and trying to fight it only reinforces the state, essentially teaching your brain that bedtime is a time for brain activity and thought. Thus getting out of bed and taking on some sort of activity till you feel ready to sleep could prove helpful. Dr. Grandner outlines some of the research and interesting studies his team is involved with currently as well as other studies on the horizon. Current research focuses on the ways sleep and sleep-related behaviors could be connected to cardiovascular disease, obesity, diabetes, neurocognitive functioning, mental health, and even longevity. Their projects have been funded by the National Collegiate Athletics Association (NCAA), the National Institute on Minority Health and Health Disparities (NIMHD), the National Heart, Lung, and Blood Institute (NHLBI), the National Institute for Environmental Health Sciences (NIEHS), and the American Heart Association (AHA). Their community-based studies consider a vast swath of issues from social environment, access to care, stress, diet, and exercise, as well as aspects of cardiometabolic functioning, to look at the ways sleep is related to each. Dr. Grandner seeks to develop new tools to help people gauge the kind of sleep they are getting and how to improve it. In regard to sleep, Dr. Grandner states, it is not something that you can command. We need to give ourselves the right environment, mentally and physically, that will allow sleep to happen. He discusses the quality versus the quantity, and the ways to evaluate that, as well as the importance of regular sleep patterns. Dr. Grandner discusses the internal body clocks that govern function, and the various types of personalities and genes that play a role in sleep schedules. He discusses the sleep-wake system versus the circadian system, which relates to the biological process that displays an endogenous, entrainable oscillation of approximately 24 hours. He explains how hormone shifts and rhythms can be changed, shifted, and blunted, and how light can help with making adjustments, in regard to the winter blues, seasonal affective disorder, etc. Dr. Grandner has published over 100 articles and chapters on myriad issues relating to sleep and health. His significant work in the field has been cited over 2,500 times. Dr. Grandner is associate editor of the recognized journal, Sleep Health, and he serves on the editorial boards of various other journals: SLEEP, Journal of Clinical Sleep Medicine, Sleep Medicine, and others. He is a sought-after speaker on the connection between sleep and good health and as such has been invited often to the National Institutes of Health, and has presented for the US Congress.

In this audio interview, Dr. Nina Radford, Director of Clinical Research and a cardiologist at Cooper Clinic, discusses cholesterol in children. Earlier this year, the National Heart Lung and Blood Institute (NHLBI) and the major pediatric associations put some new guidelines out in terms of screening cholesterol in children. The panel discusses two cholesterol screening recommendations for children. 1) The Universal Screen - consider screening cholesterol in all children, regardless of risk, sometime between 9- and 11 years of age, the age range when atherosclerosis actually starts to begin. The panel believes this is a good time to identify kids who may be from families of high risk; and it's a good time to influence children to adopt healthier habits. 2) Targeted Screen - any time, from ages 2- to 21, cholesterol might be screened if the child has any other risks for heart disease - obesity; diabetes; or high blood pressure. The child should also be screened if either parent had a stroke early in life. Dr. Radford also talks about the treatment recommendations the NHLBI makes for children who have elevated cholesterol.